 36 PM / Updated 8 minutes ago BRIEF-Rigel to Provide Business Review and Updated Phase 2 Results for Fostamatinib Reuters Staff 1 Min Read 
Jan 4 (Reuters) - Rigel Pharmaceuticals Inc: 
* RIGEL PHARMACEUTICALS - ‍FDA HAS CONFIRMED IT DOES NOT PLAN TO CONVENE ONCOLOGY DRUGS ADVISORY COMMITTEE MEETING TO DISCUSS NDA FOR FOSTAMATINIB​ 
* RIGEL PHARMACEUTICALS INC - ACTION DATE FOR FDA TO COMPLETE ITS REVIEW FOR FOSTAMATINIB IS APRIL 17, 2018 UNDER PDUFA Source text for Eikon: Further company coverage: